PepGen (PEPG) said Tuesday it has made a voluntary decision to temporarily pause its CONNECT2-EDO51 phase 2 study of PGN-EDO51 in Duchenne muscular dystrophy patients until it can review results from an ongoing study.
Pausing the study until PepGen is able to review results from the 10 mg/kg group in the phase 2 CONNECT1-EDO51 trial "will allow us to gather additional safety data, assess the impact of this dose of PGN-EDO51 on dystrophin levels, and potentially improve the design of CONNECT2," said James McArthur, CEO of PepGen.
PepGen shares were down 11% in premarket activity Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。